Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2022-07-01
|
| Серія: | Microbial Cell Factories |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12934-022-01873-7 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|